The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.

Trial Details

NCT ID

NCT05931328

Phase

PHASE2

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• thiotepa combined with pomalidomide

Locations (sample)

• Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

• Pathologically confirmed PCNSL, diagnosed according to the 2016 WHO diagnostic criteria. Previously treated with at least one course of chemotherap…
• Aged 18 to 75 years old; ECOG PS score of 0 to 4 points; Expected survival time of more than 3 months; A whole-body PET/CT and head MR (plain scan …
• Adequate organ function, defined as follows:
• Liver function: serum total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AS…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.